 |
|
COMMENTS AND OPINIONS
Type III Systemic Allergic Reaction to Natalizumab
Verena I. Leussink, MD;
Helmar C. Lehmann, MD;
Hans-Peter Hartung, MD;
Ralf Gold, MD;
Bernd C. Kieseier, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
With interest we read the article by Krumbholz et al1 in the September 2007 issue of the Archives. Natalizumab (Biogen Idec, Cambridge, Massachusetts) is a humanized monoclonal antibody against  4 integrins, recently approved by health authorities for treating relapsing forms of multiple sclerosis.2 Infusion-related allergic reactions after the intravenous application of this drug include classical type I allergic anaphylactoid hypersensitivity reactions, typically occurring within 2 hours after infusion. The incidence of these reactions in clinical trials has been reported to be 4%.3 Krumbholz et al1 recently described a patient developing a type III hypersensitivity reaction after the second infusion of natalizumab. The clinical course of this allergic reaction appeared somewhat protracted, developing during several days; however, the overall clinical picture and the association with antinatalizumab antibodies supported the view of a delayed . . . [Full Text of this Article]AUTHOR INFORMATION
RELATED ARTICLE
Delayed Allergic Reaction to Natalizumab Associated With Early Formation of Neutralizing Antibodies
Markus Krumbholz, Hannah Pellkofer, Ralf Gold, Lisa Ann Hoffmann, Reinhard Hohlfeld, and Tania Kümpfel
Arch Neurol. 2007;64(9):1331-1333.
ABSTRACT
| FULL TEXT
RELATED LETTER
Type III Systemic Allergic Reaction to Natalizumab—Reply
Markus Krumbholz, Hannah Pellkofer, Ralf Gold, Lisa Ann Hoffmann, Reinhard Hohlfeld, and Tania Kümpfel
Arch Neurol. 2008;65(6):852.
EXTRACT
| FULL TEXT
|
